The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome by Niarchou, Maria et al.
RESEARCH ARTICLENeuropsychiatric GeneticsThe Clinical Presentation of Attention
Deficit-Hyperactivity Disorder (ADHD) in
Children With 22q11.2 Deletion Syndrome
Maria Niarchou,* Joanna Martin, Anita Thapar, Michael J. Owen, and Marianne B. M. van den Bree*
MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UKManuscript Received: 25 June 2015; Manuscript Accepted: 27 August 2015This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
Financial disclosure and conflicts of interest: None reported. The
funding bodies did not participate in the collection, management,
analysis, or interpretation of data; the preparation of the manuscript; or
the decision to submit the manuscript for publication. No conflict of
interest to declare.
Grant sponsor: National Institute of Mental Health; Grant number:
NIMH 1U01MH101724-01; Grant sponsor: Wellcome Trust, Institu-
tional Strategic Support Fund (ISSF); Grant sponsor: Waterloo
Foundation; Grant number: 918-1234; Grant sponsor: Baily Thomas
Charitable Fund; Grant number: 315/1.
Correspondence to: Maria Niarchou, Ph.D. and Marianne van den Bree,
Ph.D., MRC Centre for Neuropsychiatric Genetics and Genomics,
Cardiff University, Cathays, Maindy Road, Hadyn Ellis Building, CF24
4HQ Cardiff, UK.
E-mail: niarchoum@cardiff.ac.uk (M. N.); vandenbreemb@cf.ac.uk
(M. B. M. B.)
Article first published online in Wiley Online Library
(wileyonlinelibrary.com): 24 September 2015
DOI 10.1002/ajmg.b.32378
How to Cite this Article:
Niarchou M, Martin J, Thapar A, Owen
MJ, van den Bree MBM. 2015. The Clinical
Presentation of Attention
Deficit-Hyperactivity Disorder (ADHD) in
Children With 22q11.2 Deletion Syndrome.
Am J Med Genet Part B 168B:730–738.Background: Although attention deficit-hyperactivity disorder
(ADHD) is the most prevalent psychiatric disorder in children
with 22q11.2DS, it remains unclear whether its clinical presen-
tation is similar to that in children with idiopathic ADHD. The
aim of this study is to compare the ADHDphenotype in children
with and without 22q11.2DS by examining ADHD symptom
scores, patterns of psychiatric comorbidity, IQ and gender
distribution. Methods: Forty-four children with 22q11.2DS
and ADHD (mean age¼ 9.6), 600 clinic children (mean age
¼ 10.8) and 77 children with ADHD from a population cohort
(mean age¼ 10.8) participated in the study. Psychopathology
was assessed using parent-report research diagnostic instru-
ments. Results: There was a higher proportion of females in
the 22q11.2DS ADHD sample in relation to the clinical sample
(x2¼ 18.2, P< 0.001). The 22q11.2DS group showed a higher
rate of ADHD inattentive subtype (x2¼ 114.76, P< 0.001), and
fewer hyperactive-impulsive symptoms compared to the clinical
group (z¼ 8.43, P< 0.001). The 22q11.2DS ADHD group
parents reported fewer oppositional defiant disorder/conduct
disorder symptoms (z¼ 6.33, P< 0.001) and a higher rate of
generalized anxiety disorder (x2¼ 4.56, P¼ 0.03) in relation to
the clinical group. Two percent of the 22q11.2 DS ADHD sample
had received ADHD treatment. The results were similar when
the 22q11.2 ADHD group was compared to the population
cohort ADHD group. Conclusions: The clinical presentation
of ADHDand patterns of co-morbidity in 22q11.2DS is different
from that in idiopathic ADHD. This could lead to clinical under-
recognition of ADHD in this group. Examining psychopatholo-
gy in 22q11.2DS can provide insights into the genetic origins of
psychiatric problems with implications beyond the 22q11.2DS
population.  2015 The Authors. American Journal of Medical Genetics Part
B: Neuropsychiatric Genetics Published by Wiley Periodicals, Inc.
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INTRODUCTION
22q11.2 deletion syndrome (22q11.2DS) occurs in 1:4,000 live
births [Karayiorgou et al., 2010], is caused by a microdeletion
of 40 genes, and represents one of the strongest known genetic
risk factors for developing schizophrenia (approximately 25–30%2015 The Authors. American Journal of Medical Genetics Part B: Neucompared to 1% in the general population) [Murphy et al., 1999].
Children with 22q11.2DS are at high risk for a wide range of
psychiatric problems, including mood and anxiety disorders
[Schneider et al., 2014] and tend to have elevated rates of neuro-
developmental disorders, including intellectual disability and
impairments in a range of cognitive functions [Niarchou et al.,
2014]. We previously reported that children with 22q11.2DS had a
similar distribution of IQ scores as sibling controls, but that the
mean was 30 points lower [Niarchou et al., 2014].ropsychiatric Genetics Published by Wiley Periodicals, Inc. 730
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the most common form of psychopathology in children with
22q11.2 DS (with reported rates estimated at 37% in children
and 24% in adolescents [Schneider et al., 2014]), there is a dearth of
studies comparing the clinical features of ADHD in 22q11.2DS
with those in idiopathic ADHD. Although most studies of psy-
chopathology are based on populations of diverse etiology, indi-
viduals with 22q11.2DS constitute a genetically relatively
homogeneous group that can contribute important insights into
genotype–phenotype relationships and diseasemechanisms [Owen
et al., 2010]. Moreover, improved understanding of the clinical
presentation of ADHD in 22q11.2DS can contribute to improved
recognition and treatment.
We are aware of a single study [Antshel et al., 2007] which
compared 34 children with 22q11.2DS and ADHD (52% males,
mean age 10 years) and 280 children with ADHD without this
deletion (50% males, mean age 10 years). The authors found that
children with 22q11.2DS were more likely to have the DSM-IV
inattentive subtype of ADHD (79 vs. 20%), whereas the DSM-IV
combined subtype was more common in children with idiopathic
ADHD (21 vs. 78%, respectively). More work is needed to fully
characterize the ADHD phenotype in children with 22q11.2DS.
The aim of the current study was to compare the ADHD
phenotype in children with and without 22q11.2DS by examining
total ADHD symptom scores, comorbid psychopathology, and
patterns of IQ and gender distribution. Children with 22q11.2DS
who met DSM-IV diagnostic criteria for ADHD (22q11.2DS
ADHD) were compared with a group of children with ADHD
recruited through child/adolescent psychiatric services (clinical
ADHD). As a supplementary analysis, we further compared the
22q11.2DS and ADHD group with a sample of children with
ADHD identified from a large population cohort (population-
based ADHD).
METHODS
Samples
22q11.2DS ADHD. Participants were drawn from three dif-
ferent studies. Children with 22q11.2DS and ADHD were selected
from an ongoing study of children with copy number variations
(the ExperienCes of people witH cOpy number variants study
(ECHO study; see website: http://medicine.cardiff.ac.uk/
psychological-medicine-neuroscience/areas-research/copy-
number-variant-research/research-projects/). ECHO participants
are referred from 11 genetics clinics within the UK, as well as a
number of charities and also through word of mouth. To date, 113
children with 22q11.2DS have taken part in the ECHO study. For
the purpose of the present study, children with 22q11.2DSmeeting
a DSM-IV research diagnosis of ADHD (n¼ 44; 41% of total
sample), after conducting a research diagnostic interview (see
below), were included. The mean age of this sample was 9.61
(SD¼ 2.1), range: 6–14 years. Only one child was receiving ADHD
treatment in form of stimulant medication. Presence of the dele-
tion was confirmed for all children with 22q11.2DS by the relevant
Medical Genetics laboratories. The study was approved by the
appropriate research National Health System (NHS) ethics and
R&D committees. The carers of the children provided informedwritten consent to participate prior to recruitment and assent/
consent was also obtained from the children.
Clinical ADHD. Six hundred children with a confirmed clin-
ical diagnosis of DSM-IV/DSM-III-R ADHD (mean age: 10.8
[SD¼ 3.0, range: 6–18] years) (clinical ADHD) were recruited
from child psychiatry and pediatric outpatient clinics for a ge-
nome-wide association and CNV study of ADHD [see Williams
et al., 2010, 2012; Stergiakouli et al., 2012]. Diagnosis was con-
firmed by a research diagnostic interview. Approval was obtained
from the North West England and Wales Multicenter Research
Ethics Committee and written informed consent was obtained
from the carers of the children, and assent/consent from the
children. None of this sample had the 22q11.2 deletion as con-
firmed by genotyping on the Illumina (San Diego) Human660W-
Quad BeadChip. The CNV protocol is further described elsewhere
[Stergiakouli et al., 2012].
Population cohort ADHD. Seventy-seven received a research
diagnosis of DSM-IV ADHD (mean age: 10.8 (0.2), range: 10–12)
(population-based ADHD). These were recruited for the Avon
Longitudinal Study of Parents and Children (ALSPAC). ALSPAC
started in 1991–1992, when all pregnant women residing in the
southwest of England were recruited. The initial ALSPAC cohort
consisted of 14,062 live births and 13,988 infants still alive at
12 months [Boyd et al., 2012, Fraser et al., 2012]. Ethical approval
was obtained from the ALSPAC’s Law and Ethics Committee and
the Local Research Ethics Committees. Parents who enrolled their
children into ALSPAC provided written informed consent at the
time of the enrollment and they or their child are free to withdraw
at any time. The study website contains details of all available data
through a fully searchable data dictionary (http://www.bris.ac.uk/
alspac/researchers/data-access/data-dictionary/).Measures
ADHDand other psychiatric comorbidities. 22q11.2DSADHD
and clinical ADHD. The parent version of the Child and Ado-
lescent Psychiatric Assessment (CAPA) [Angold et al., 1995] was
used to obtain a DSM-IV-TR research diagnosis of ADHD for both
the 22q11.2DS ADHD and the clinical ADHD samples. The CAPA
is a semi-structured interview providing categorical diagnoses as
well as symptom counts of psychiatric disorders. Additionally,
oppositional defiant disorder (ODD), conduct disorder (CD),
generalized anxiety disorder (GAD), separation anxiety (SA),
major depressive disorder (MDD), and tic disorder were also
assessed. Symptom counts were derived from responses to ques-
tions about worries, depression, sleep, andODDbehavior/conduct
problems. For both samples, all interviews were undertaken by
trained psychologists, who were supervised by a consultant Child
and Adolescent Psychiatrist.
Population cohort sample. The parent Development and
Well-Being Assessment (DAWBA) [Goodman et al., 2000] was
used to obtain DSM-IV-TR research diagnoses of ADHD for the
ALSPAC birth cohort. The DAWBA questionnaire was sent out to
mothers when their study child was 10 years old. It includes
questions that ask for details of the symptoms relevant to a number
of psychiatric disorders and then further clarifying the severity and
duration of the symptoms and their effect on the child’s life and
732 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bdevelopment. DAWBA symptom ratings were scored on a 5-point
scale, ranging from “absent” to “definitely present.”
Taking into account evidence showing that questionnaires may
over-estimate prevalence of psychopathology (e.g., [Laurens et al.,
2007]) and in order to allow for comparisons with the diagnosis
and symptoms rates of the CAPA, we counted ADHD symptoms in
the DAWBA as present only if the child was reported to have a
symptom “a lotmore than others” or “definitely.” This resulted in a
research diagnosis of ADHD (using all DSM-IV criteria) for age
10 years in 77 (1%), out of a total of 7,729 ALSPAC children with
available DAWBA data. DSM-IV-TR diagnoses of ODD, GAD, SA,
and MDD were also obtained from the DAWBA. However, infor-
mation contributing to diagnoses of tic disorder and sleep symp-
toms was not available for the ADHD population cohort sample
and CD diagnoses were not available for age 10 in ALSPAC.
Therefore, for these diagnoses, comparisons were limited to the
22q11.2DS ADHD and the clinical ADHD sample.
Symptom counts of ODD/CD symptoms were also calculated.
Symptom counts for worries and depression were not included in
the analysis as the questions were not sufficiently comparable to the
ones included in the CAPA interview that was administered in the
22q11.2DSADHDand the clinical ADHD samples. For example, in
the depression section of the CAPA interview, the symptom
“distinct quality of depressed mood” was assessed with the ques-
tions: “When s/he’s miserable does s/he seem to feel the same as
when something sad happens or s/he sees a sad movie or program?
Is this feeling of being miserable different than the feeling of being
sad” while the most comparable question from the DAWBA was
“child has been grumpy or irritable in a way that was out of
character.”
IQ. IQ tests were administered by trained raters in all three
studies. In the 22q11.2DS ADHD sample, the Wechsler Abbrevi-
ated Scale of Intelligence (WASI; 4 subtests) [Wechsler, 1999] was
administered. IQ scores were unavailable for three children with
22q11.2DS. In the clinical ADHD sample, all the subtests of the
Wechsler Intelligence Scale for Children (WISC-III or WISC-IV)
[Wechsler et al., 1992, 2003] were administered and parents were
asked to withhold stimulant medication from their child for 24 hr
prior to testing. IQ scores were available for 550/600 children.
Finally, the WISC-III (8 subtests) [Wechsler et al., 1992] was
administered in the population cohort ADHD sample, whenTABLE I. Socio-Demographic
22q11.2DS ADHD (%) Cl
Social group
Low 8
Middle 73
High 19
Mother’s highest educational qualification
None 12
GCSEs or O’levels 33
A levels 33
Degree or higher 23
SES was classified based on the occupation of the main family wage earner using the UK Standard Occ
unskilled workers/unemployed; medium: manual and non-manual skilled/partially skilled workers; hchildren were 8 years old, in a short form where alternate items
were used for all subtests apart from the coding subtest. IQ was
available for 48/77 children in this sample. However, information
on stimulant medication is not available at this age for this sample.Data Analysis
Data analysis was conducted using Stata (version 13) for Windows
7. To compare themean differences in age, IQ and symptom counts
between the two groups, t-tests were used or in the case of non-
normally distributed variables, Mann–Whitney U tests were used.
Chi-square tests were used to compare the rates of psychopathol-
ogy between the groups. TheWilcoxonmatched-pairs signed-rank
test was used to examine whether the ADHD phenotype between
the 22q11.2DS and the clinical ADHD sample was similar after
matching for IQ, sex, and age.RESULTS
Table I provides a socio-demographic description of the samples.
The clinical ADHD sample came from a lower socio-economic
background. Moreover, a greater proportion of mothers of chil-
dren in the clinical ADHD sample had less formal education than
those from the other two groups. There were no differences in
highest maternal education level between the groups.Descriptive Group Differences
There were age and gender differences between the 22q11.2DS
ADHD and the clinical ADHD samples (see Table II). The
22q11.2DSADHD sample was on average younger than the clinical
ADHD sample (P¼ 0.01) and there was a higher proportion of
males in the clinical than in the 22q11.2DS sample (P< 0.001).
There were no IQ differences between the 22q11.2DS ADHD and
the clinical ADHD samples (P¼ 0.06).Comparison of ADHD Subtypes, Symptoms, and
Other Psychiatric Comorbidities
The 22q11.2DSADHD sample had a considerably higher rate of the
ADHD inattentive subtype (61%) compared to the clinical ADHDDescription of the Samples
inical ADHD (%) Population cohort ADHD (%) x2 P
54 0 95.2 <0.001
33 46
13 54
28 15 31.6 <0.001
49 50
13 27
9 8
upation Classification (Office of National Statistics, 2001). Three SES categories were defined (low:
igh: professional and managerial workers).
TABLE II. Comparisons of Demographic Factors, ADHD Subtypes, Scores, and Other Psychiatric Comorbidities
22q11.2DS ADHD (n¼ 44) Clinical ADHD (n¼ 600)
Variable Mean(SD) or % Mean(SD) or % x2, z, t P
Age 9.61 (2.07) 10.81 (2.99) t¼ 2.61 0.01
Sex (% males) 59% 84% x2¼ 18.2 <0.001
IQ 78.17 (12.42) 82.27 (13.37) t¼ 1.90 0.06
ADHD comparisons
Inattentive subtype 61% 8% x2¼ 114.76 <0.001
Hyperactive–impulsive subtype 9% 10%
Combined subtype 30% 82%
ADHD symptoms—inattention 7.40 (1.20) 7.62 (1.53) z¼ 1.83 0.07
ADHD symptoms—hyperactivity–impulsivity 4.51 (2.47) 7.77 (1.50) z¼ 8.43 <0.001
ADHD symptoms—total 11.91 (2.78) 15.39 (2.33) z¼ 7.26 <0.001
Other psychopathology
Oppositional defiant disorder 34% 46% x2¼ 2.37 0.12
Conduct disorder 0% 21% x2¼ 11.61 <0.001
Generalized anxiety disorder 9% 3% x2¼ 4.56 0.03
Separation anxiety disorder 11% 4% x2¼ 2.00 0.16
Major depressive disorder 0% 1% x2¼ 0.62 0.43
Tic disorder 11% 10% x2¼ 0.09 0.77
ODD/CD symptoms 3.86 (2.02) 6.69 (2.80) z¼ 6.33 <0.001
Worries symptoms 1.41 (1.70) 1.05 (1.56) z¼1.41 0.16
Depression symptoms 0.62 (1.06) 0.47 (0.95) z¼1.11 0.27
Sleep symptoms 1.42 (1.35) 1.20 (1.15) z¼0.83 0.41
ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder.
The bold values signify a P-value 0.05.
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lower rate of the ADHD combined subtype (30%) in relation to the
clinical ADHD group (82%) (P< 0.001). With regard to ADHD
symptoms, the two groups were similar in terms of inattention
symptoms (P¼ 0.07). However, the clinical ADHD sample had
more hyperactive-impulsive (P< 0.001) and total symptoms
(P< 0.001) than the 22q11.2DS ADHD group (Fig. 1).
The 22q11.2DS ADHD sample had higher GAD rates than the
clinical ADHD sample (P¼ 0.03). Rates of ODD, separation
anxiety disorder (SAD), MDD diagnoses, and tic disorder were
similar between the groups. However, the clinical ADHD sample
had a higher rate of CD diagnosis compared to the 22q11.2DS
ADHD sample (P< 0.001).
With regard to ODD/ CD symptoms, the clinical ADHD sample
showed higher levels compared to the 22q11.2DS ADHD sample
(P< 0.001), while there were no differences in the rate of tic
disorder or in symptom counts of depression, worries, and sleep
problems.Comparisons Taking IQ, Age, and Gender Into
Account
We repeated these analyses, excluding children with (IQ< 70)
(27% of 22q11.2DS sample; 14% of clinical sample) to evaluate
whether intellectual disability IQ explained these findings. The
results were found to be broadly similar to those based on the full
samples (Table III).Analyses based on males only (59% of 22q11.2DS ADHD
sample; 84% of clinical ADHD sample) also yielded comparable
results (Table IV).
Wematched the 22q11.2DSADHDsample and the clinical ADHD
sample on age, IQ, and gender and repeated the analyses. The results
remained similar (Table V), with the exception that compared to our
previous analyses, differences in GAD rates were no longer present
while there was some evidence that the inattention symptoms differed
between the 22q11.2DS ADHD and the clinical group (P¼ 0.04).
Finally, we repeated the analyses by comparing the 22q11.2DS
ADHD group with a population-based ADHD group and the
results were also similar (Table VI) with the difference that the
population-based ADHD sample had a higher mean IQ than the
22q11.2DS ADHD.
DISCUSSION
The ADHD Phenotype Associated With
22q11.2DS
The results of this study suggest that the ADHD phenotype is
different in children with 22q11.2DS compared to children with
ADHD recruited through child psychiatry and pediatric outpatient
clinicsor identified fromapopulationcohort.Toourknowledge,our
study is the first to report that children with 22q11.2DS and ADHD
show fewer ODD/CD symptoms when compared to children with
idiopathic ADHD and children from a population-based study.
Moreover, our study indicated that children with 22q11.2DS and
FIG. 1. ADHD symptoms across groups. [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.
com/journal/ajmgb].
TABLE III. Comparisons of Demographic Factors, ADHD Subtypes, Symptom Scores, and Other Psychiatric Comorbidities Including Only
Subjects With IQ 70
22q11.2DS ADHD (n¼ 32) Clinical ADHD (n¼ 473)
Variable Mean (SD) or % Mean (SD) or % x2, t, z P
Age 9.22 (1.69) 10.69 (2.89) t¼ 2.86 0.004
Sex (% males) 59% 84% x2 = 13.12 <0.001
IQ 82.69 (9.62) 85.88 (10.40) t¼ 1.69 0.09
ADHD comparisons
Inattentive subtype 56% 9% x2 = 68.03 <0.001
Hyperactive–Impulsive subtype 9% 10%
Combined subtype 34% 81%
ADHD symptoms —inattention 7.29 (1.24) 7.60 (1.56) z¼ 1.85 0.07
ADHD symptoms—hyperactivity–impulsivity 4.61 (2.62) 7.73 (1.54) z¼ 6.77 <0.001
ADHD symptoms—total 11.90 (3.02) 15.33 (2.38) z¼ 5.85 <0.001
Other psychopathology
Oppositional defiant disorder 31% 48% x2¼ 3.28 0.07
Conduct disorder 0% 19% x2 = 7.16 0.01
Generalized anxiety disorder 13% 3% x2 = 6.42 0.01
Separation anxiety disorder 13% 3% x2 = 3.90 0.05
Major depressive disorder 0% 1% x2¼ 0.35 0.55
Tic disorder 13% 11% x2¼ 0.11 0.74
ODD/CD symptoms 4.07 (1.65) 6.60 (2.81)6.60 (2.81) z¼ 5.15
Worries symptoms 1.87 (1.80) 0.97 (1.44) z¼3.02 0.003
Depression symptoms 0.70 (1.18) 0.46 (0.89) z¼1.24 0.22
Sleep symptoms 1.42 (1.43) 1.17 (1.12) z¼0.61 0.54
ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder.
The bold values signify a P-value 0.05.
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TABLE IV. Comparisons of Demographic Factors, ADHD Subtypes, Symptom Scores, and Other Psychiatric Comorbidities Including
Only Males
22q11.2DS ADHD (n¼ 26) Clinical ADHD (n¼ 506)
Variable Mean (SD) or % Mean (SD) or % x2, t, z P
Age 9.41(1.95) 10.89(2.95) t¼2.53 0.01
IQ 79.04(12.25) 82.52(13.44) t¼1.24 0.22
ADHD comparisons
Inattentive subtype 62% 8% x2¼77.77 P<0.001
Hyperactive–impulsive subtype 8% 9%
Combined subtype 30% 83%
ADHD symptoms—inattention 7.54(1.10) 7.62(1.53) z¼1.05 0.29
ADHD symptoms—hyperactivity–impulsivity 4.96(2.34) 7.79(1.52) z¼6.27 P<0.001
ADHD symptoms—total 12.5(2.66) 15.41(2.31) z¼5.17 P<0.001
Other psychopathology
Oppositional defiant disorder 35% 47% x2¼1.42 0.23
Conduct disorder 0% 20% x2¼6.47 0.01
Generalized anxiety disorder 4% 2% x2¼0.19 0.66
Separation anxiety disorder 10% 3% x2¼1.64 0.20
Major depressive disorder 0% 1% x2¼0.27 0.60
Tic disorder 15% 11% x2¼0.42 0.52
ODD/CD symptoms 4.04(1.82) 6.69(2.77) z¼4.85 P<0.001
Worries symptoms 1.24(1.60) 1.02(1.52) z¼-0.78 0.44
Depression symptoms 0.64(1.04) 0.45(0.88) z¼-1.30 0.20
Sleep symptoms 1.31(1.26) 1.17(1.12) z¼-0.46 0.64
ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder.
The bold values signify a P-value 0.05.
TABLE V. Matched Comparisons (Age, Sex, and IQ) of ADHD Symptoms and Other Psychiatric Comorbidities
Variable
22q11.2DS ADHD (n¼ 44) Clinical ADHD (n¼ 44)
x2, z PMean (SD) or % Mean (SD) or %
Age 9.14 (2.08)
Sex 59% males
IQ 78.6 (11.9)
ADHD comparisons
ADHD symptoms—inattention 7.40 (1.20) 7.86 (1.3) z¼ 2.07 0.04
ADHD symptoms—hyperactivity–impulsivity 4.51 (2.47) 7.98 (1.2) z¼ 5.10 <0.001
ADHD symptoms—total 11.91 (2.78) 15.84 (2.1) z¼ 4.96 <0.001
Other psychopathology
Oppositional defiant disorder 34% 45% x2¼ 0.33 0.56
Conduct disorder 0% 24% x2¼3.44 <0.001
Generalized anxiety disorder 9% 0% x2¼ 1.21 0.23
Separation anxiety disorder 11% 7% x2¼ 0.44 0.66
Major depressive disorder 0% 0% n/a n/a
Tic disorder 11% 7% x2¼ 0.44 0.51
ODD/CD symptoms 3.86 (2.02) 7.42 (2.7) z¼ 4.87 <0.001
Worries symptoms 4.24 (5.12) 2.16 (3.8) z¼1.76 0.08
Depression symptoms 4.87 (4.59) 4.66 (3.6) z¼0.28 0.78
Sleep symptoms 1.37 (1.32) 1.07 (1.2) z¼1.05 0.30
ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder.
The bold values signify a P-value 0.05.
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TABLE VI. Comparisons of Demographic Factors, ADHD Subtypes, Scores, and Other Psychiatric Comorbidities Between the 22q11.2DS
and the Population-Based Sample
Variable
22q11.2DS ADHD (n¼ 44) Population-based sample (n¼ 77)
x2, z, t PMean (SD) or % Mean (SD) or %
Age 9.61 (2.07) 10.80 (0.21) t¼ 5.00 <0.001
Sex 59% 88% x2¼ 13.79 <0.001
IQ 78.17 (12.42) 99.25 (20.70) t¼ 5.77 <0.001
ADHD comparisons
Inattentive subtype 61% 26% x2¼ 114.87 <0.001
Hyperactive–impulsive subtype 9% 14%
Combined subtype 30% 60%
ADHD symptoms—inattention 7.40 (1.20) 7.20 (2.01) z¼ 0.37 0.71
ADHD symptoms—hyperactivity–impulsivity 4.51 (2.47) 6.78 (2.61) z¼ 4.69 <0.001
ADHD symptoms—total 11.91 (2.78) 13.97 (3.45) z¼ 9.36 <0.001
Other psychopathology
Oppositional defiant disorder 34% 44% x2¼ 1.18 0.28
Conduct disorder 0 n/a n/a n/a
Generalized anxiety disorder 9% 10% x2¼ 0.05 0.82
Separation anxiety disorder 11% 8% x2¼ 0.21 0.65
Major depressive disorder 0% 3% x2¼ 1.16 0.28
Tic disorder 11% n/a n/a n/a
ODD/CD symptoms 3.86 (2.02) 5.28 (3.13) z¼ 2.23 0.03
Worries symptoms 1.41 (1.70) 1.81 (2.28) z¼ 0.95 0.34
Depression symptoms 0.62 (1.06) 1.27 (1.89) z¼ 1.28 0.20
ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder.
The bold values signify a P-value 0.05.
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diagnoses when compared to children with idiopathic ADHD.
Another noticeable difference in ADHD subtypes was also present.
Themajorityofchildrenwith22q11.2DSmetcriteria for theDSM-IV
inattentive ADHD subtype, whereas the majority of children in the
other two samples had theDSM-IV combined subtype. This appears
to be because while they endorsed a similar number of inattention
symptoms, they endorsed fewer hyperactive and impulsive symp-
toms than the clinical and population cohort of children with
ADHD. This is in agreement with a previous study [Antshel et al.,
2007], where higher rates of ADHD inattentive subtype and lower
rates of ADHD combined subtype were found in children with
22q11.2DS compared to children with idiopathic ADHD.
Studies comparing psychiatric comorbidities in populations
with ADHD have indicated that children with the inattentive
ADHD subtype show more anxiety/depression symptoms in com-
parison to children with the hyperactive ADHD subtype, who tend
to show more conduct problems (e.g., [Graetz et al., 2001]).
Children with 22q11.2DS and ADHD endorsed mostly the inat-
tentive subtype of ADHD and showed lower rates of CD diagnoses
and increased anxiety in relation to the other two groups. ADHD
subtypes did not explain differences in the rates of anxiety/depres-
sion symptoms and conduct problems (data not presented).
Therefore, the differences in the rates of CD and anxiety in the
ADHD children with 22q11.2DS and children with idiopathic
ADHD are more likely to be consequences of the deletion ratherthan being secondary to the ADHD symptoms. Moreover, in the
present study, our results remained largely similar when the
analysis was restricted to children without intellectual disability
(i.e., IQ 70), supporting the view that while the symptom
patterns and comorbidities of ADHD in 22q11.2DS are different
from those in idiopathic ADHD, this cannot be attributed to the
effects of intellectual disability.Gender Differences
Our results remained similar when the analyses included only
males. Interestingly, ADHD was not more common in males
with 22q11.2DS, while the typical male preponderance was seen
in the population cohort and clinical samples. Whether this
represents a particular feature of the ADHD phenotype in
22q11.2DS or a statistical power issue remains to be resolved. It
is possible that the deletion of one or more genes within the
genetically homogeneous 22q11.2DS sample to some degree neg-
ates gender-specific liability to neurodevelopmental disorders such
as ADHD. The current literature in 22q11.2DS is inconsistent and
cannot elucidate this matter. Findings from the largest study of
22q11.2DS to date [Schneider et al., 2014] showed a higher male
prevalence of ADHD (males 60%); however, other studies have
reported a preponderance in females [Zagursky et al., 2006].
Studies of non-deleted ADHD populations have shown that
females may be more likely to manifest inattentive rather than
NIARCHOU ET AL. 737hyperactive-impulsive problems [Gershon and Gershon, 2002],
although this has not always been confirmed [Graetz et al., 2001,
Neuman et al., 2005]. Moreover, studies have also suggested that
females with intellectual disabilitymight be at higher risk of ADHD
than females without intellectual disability [Pearson et al., 1996]. In
our 22q11.2DS sample, females were not more likely to have the
inattentive subtype than males and this remained the case when
individuals with IQ< 70 were excluded from the analysis. One
previous 22q11.2DS study examining gender differences in indi-
viduals with intellectual disability and ADHD found more males
than females with intellectual disability and/or ADHD [Niklasson
et al., 2009]. Most 22q11.2DS children recruited in this previous
studywere ascertained frompediatric and speech pathology clinics,
whereas most individuals in our sample were ascertained through
genetics clinics, which could explain the differences in findings.Clinical Implications
Given the high rates of ADHD and its adverse impact on function-
ing, early identification and treatment of the disorder in 22q11.2DS
is of great importance. Our findings may help to alert clinicians to
the presentation of ADHD in the 22q11.2DS group. Moreover,
future research will need to assess long-term benefits versus risks of
stimulant medication given the elevated rate of psychosis in this
group. Future research could also investigate the benefits of other
interventions commonly used in ADHD (e.g., non-stimulant
medications, behavioral interventions, such as parentmanagement
training). Psychiatric comorbidity has been associated with more
adverse outcomes which may be due to the combined effects of the
disorders [DuPaul et al., 2013]. We have previously reported high
rates of comorbidity in children with 22q11.2DS with 37.5% of
children having both ADHD and at least one anxiety disorder
[Niarchou et al., 2014]. The high rates of comorbid intellectual
disability and anxiety disorders co-occurring together with ADHD
in 22q11.2DS certainly warrant further clinical attention aiming to
reduce the negative sequelae of the disorder [Tarver et al., 2014].Strengths and Limitations
This is the largest study to date to compare children with
22q11.2DS and a large sample of childrenwith ADHD from clinical
settings. Nevertheless, differences in methodologies and ascertain-
ment strategies need to be kept in mind when interpreting the
findings. The children in the longitudinal population cohort had
already been participants for 10 years at the time the ADHD and
other assessments used in this study were conducted and attrition
bias may have influenced the findings. Moreover, referral bias
could also apply to both the 22q11.2DS sample (given that people
from a higher socio-economic background are more likely to be
tested in genetics clinics) and the clinical ADHDgroup (taking into
account that disruptive children are more likely to be referred for a
clinical mental health assessment). This could also explain the low
rates of inattentive subtype among children in the clinical cohort.
Ideally, our findings should have been based on reports from
multiple sources; however, obtaining teacher reports was outside
the remit of the 22q11.2 DS study. Another limitation is that we did
not examine autism-spectrum disorder, although this is reportedto frequently co-occur with ADHD in 22q11.2DS [Niklasson et al.,
2009, Niarchou et al., 2014] as well as in idiopathic ADHD [Kotte
et al., 2013].CONCLUSIONS
The ADHD phenotype in 22q11.2DS is different in comparison to
the ADHD phenotype of clinical and population cohort samples.
Children with 22q11.2DS and ADHD showed fewer ODD/CD
symptoms, lower rates of CD diagnoses, and higher rates of GAD
diagnoses. The study of psychopathology in 22q11.2DS and in
other CNVs that have been recently implicated in risk of ADHD
[Williams et al., 2010, Lionel et al., 2011] could improve our
understanding of phenotype/genotype relationships, especially
given that these chromosomal conditions are likely to represent
genetically more homogeneous sub-groups of ADHD.ACKNOWLEDGMENTS
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